Price movement over the last 24 hours
Abeona Therapeutics Inc vs Newegg Commerce Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Newegg Commerce Inc trades at $14.07 (market cap $314.92M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NEGG | |
|---|---|---|
Market Cap | $373.32M | $314.92M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $128.09 |
52-Week Low | $4.17 | $14.72 |
Enterprise Value | $228.22M | $313.72M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NEGG trades at $14.94 with minimal daily movement (+0.2%). The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment. Recent financials reveal modest revenue growth to $1.44B in 2025, though profitability remains challenged with a net loss of $4.88M. The company is investing in AI shopping experiences and promotional events to drive growth.
While analyst consensus is bullish (100% buy rating), fundamental weaknesses including negative cash flow from operations and thin margins present risks. The stock's valuation appears stretched with a P/E of 57.14, suggesting limited near-term upside without significant earnings improvement.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →